Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Invitae | RCV000468743 | SCV000554767 | benign | Neuroblastoma, susceptibility to, 3 | 2024-02-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV000561458 | SCV000672471 | likely benign | Hereditary cancer-predisposing syndrome | 2016-11-30 | criteria provided, single submitter | clinical testing | This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Genetic Services Laboratory, |
RCV001821311 | SCV002070894 | likely benign | not specified | 2021-10-25 | criteria provided, single submitter | clinical testing | |
Sema4, |
RCV000561458 | SCV002528378 | benign | Hereditary cancer-predisposing syndrome | 2020-12-10 | criteria provided, single submitter | curation | |
KCCC/NGS Laboratory, |
RCV000468743 | SCV004016955 | benign | Neuroblastoma, susceptibility to, 3 | 2023-07-07 | criteria provided, single submitter | clinical testing | |
Ce |
RCV003884553 | SCV004699934 | likely benign | not provided | 2023-12-01 | criteria provided, single submitter | clinical testing | ALK: BP4, BP7, BS2 |